Sugi Predict

Sugi Predict / Compounds / SCHEMBL4778533

SCHEMBL4778533

SCHEMBL4778533

O=C1CN(C(=O)N2CCC[C@H](NC(=O)C34CC5CC(C3)C(O)C(C5)C4)C2)CCN1

nearest known ligand 0.40

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ F2R P25116 1/20 0.38
▸ CCR2 P41597 2/20 0.38
▸ EPHX1 P07099 2/20 0.38
▸ KMT2A Q03164 2/20 0.37
▸ ALDH1A1 P00352 2/20 0.34
▸ POLB P06746 1/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ LMNA P02545 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ ITGB1 P05556 1/20 0.33
▸ ITGA4 P13612 1/20 0.33
▸ RAB9A P51151 1/20 0.32
▸ HSD11B1 P28845 3/20 0.32
▸ GAA P10253 1/20 0.31
▸ CNR2 P34972 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14540692 1.00 F2R (0.38) F2RCCR2EPHX1KMT2AALDH1A1
SCHEMBL4835577 1.00 F2R (0.38) F2RCCR2EPHX1KMT2AALDH1A1
SCHEMBL4794135 0.86 EPHX1 (0.46) EPHX1KMT2AALDH1A1SMN1; SMN2LMNA
SCHEMBL14540867 0.86 EPHX1 (0.46) EPHX1KMT2AALDH1A1SMN1; SMN2LMNA
SCHEMBL4793633 0.85 EPHX1 (0.45) EPHX1KMT2AALDH1A1SMN1; SMN2LMNA
SCHEMBL14540971 0.83 EPHX1 (0.36) CCR2EPHX1KMT2AALDH1A1SMN1; SMN2
SCHEMBL4769795 0.83 EPHX1 (0.36) CCR2EPHX1KMT2AALDH1A1SMN1; SMN2
SCHEMBL4769808 0.83 EPHX1 (0.36) CCR2EPHX1KMT2AALDH1A1SMN1; SMN2
SCHEMBL4767981 0.82 EPHX1 (0.43) EPHX1KMT2AALDH1A1SMN1; SMN2LMNA
SCHEMBL4793588 0.81 EPHX1 (0.42) F2REPHX1KMT2AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1931652-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2008-06-18 — — EP claimed
WO-2007038138-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2007-04-05 — — WO claimed
US-20070066584-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2007-03-22 — — US claimed
EP-1931652-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2008-06-18 — — EP disclosed
WO-2007038138-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2007-04-05 — — WO disclosed
US-20070066584-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2007-03-22 — — US disclosed
US-20070066584-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2007-03-22 — — US disclosed
US-20070066584-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2007-03-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070066584-A1 Amido compounds and their use as pharmaceuticals HSD11B1, CYP11B1, HSD11B2 F2R 571/4885CCR2 4476/4885EPHX1 378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.